Kiranmayee Lanka
Critical Care Medicine · Cincinnati, OHNPI 1003072943
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,836 of the $6,158 with a category attached, or 62.3%. 26 manufacturers reported payments, led by Johnson & Johnson at 32.5% of the total. Among critical care medicine clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $28.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Pulmonx Corporation$2K
- GSK$1K
- Medical Device Business Services, Inc.$231
- Sanofi$195
- AstraZeneca$173
- plus $1K from 20 others
What the payments were for
- Travel & lodging$2,32038%
- Food & beverage$3,83662%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 23 | $2,001 |
| Pulmonx Corporation | 20 | $1,521 |
| GSK | 78 | $1,009 |
| Medical Device Business Services, Inc. | 7 | $231 |
| Sanofi | 9 | $195 |
| AstraZeneca | 12 | $173 |
| Genentech USA, Inc. | 8 | $128 |
| Boehringer Ingelheim | 5 | $102 |
| Sunovion Pharmaceuticals Inc. | 14 | $99 |
| Mylan Specialty L.p. | 4 | $83 |
| Amgen | 3 | $69 |
| Mayne Pharma Commercial LLC | 3 | $62 |
| Philips North America LLC | 4 | $62 |
| Astellas Pharma US Inc | 4 | $61 |
| Inogen, Inc. | 3 | $61 |
| Regeneron Healthcare Solutions, Inc. | 3 | $60 |
| Grifols USA, LLC | 2 | $39 |
| Electromed, Inc. | 3 | $34 |
| Merck | 2 | $33 |
| Portola Pharmaceuticals, LLC | 2 | $32 |
| Medtronic | 1 | $23 |
| Covis Pharma GmbH | 1 | $22 |
| Advanced Respiratory, Inc | 1 | $19 |
| Veran Medical Technologies, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| United Therapeutics Corporation | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,158 in reported general payments places this provider in the 90th percentile of 285 critical care medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 223 | $219,438 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 155 | $145,748 |
| Fasenra PenBenralizumab | 11 | $61,822 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $51,604 |
| Advair HfaFluticasone Propion/Salmeterol | 56 | $36,048 |
| Spiriva RespimatTiotropium Bromide | 44 | $32,228 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $20,681 |
| DuleraMometasone/Formoterol | 34 | $14,557 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 324 | $9,686 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $9,586 |
| Arnuity ElliptaFluticasone Furoate | 29 | $7,112 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $6,424 |
| Roflumilast | 64 | $5,120 |
| Ventolin HfaAlbuterol Sulfate | 36 | $3,388 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $2,679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,009 | $278,154317 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $173 | $155,334181 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $102 | $52,91072 claims |
| MerckDulera | $33 | $14,55734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 285 critical care medicine providers in Ohio.
Other critical care medicine in Cincinnati
- Sadia BenzaquenCincinnati$15K
- Maria IndiharCincinnati$8K
- Geoffrey LohCincinnati$7K
- Thomas PrestonCincinnati$5K
- Muhammad KhawarCincinnati$5K
- Christopher OrabellaCincinnati$5K
- Adam ColeCincinnati$4K
- Christopher SchmittCincinnati$4K
- Eric WeinsteinCincinnati$4K
- Jonathan HendersonCincinnati$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.